Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1137390

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether a date has been set for Vertex pharmaceuticals, NICE and NHS England to convene a further meeting to discuss how the cystic fibrosis drug Orkambi can be made available to patients.
	tabling member printed	Baroness Morgan of Huyton
	uin	HL16997
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16998 HL16999 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137391

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the impact of the lack of availability of Orkambi on patients with cystic fibrosis; and what plans they have to discuss this issue with (1) patients, and (2) other interested parties.
	tabling member printed	Baroness Morgan of Huyton
	uin	HL16998
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16997 HL16999 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137392

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans the Secretary of State for Health and Social Care has to intervene in the ongoing negotiations between Vertex pharmaceuticals, NICE and NHS England on the price of the cystic fibrosis drug Orkambi to ensure that it is made available to patients as soon as possible.
	tabling member printed	Baroness Morgan of Huyton
	uin	HL16999
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16997 HL16998 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137099

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gambling: Rehabilitation
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what are the projected funding costs to the NHS of the new gambling-related harm clinics, announced on 23 June.
	tabling member printed	The Lord Bishop of St Albans
	uin	HL16963
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>As part of its NHS Long Term Plan, NHS England has made a commitment to invest in clinics to help more people with serious gambling problems. NHS England published its Long Term Plan Implementation Framework on 5 July 2019. The projected funding for gambling clinics was not separately identified and will be provided at a later date.</p><p>The first National Health Service gambling clinic for children will open this year as part of a new network of services for addicts being rolled out. Up to 15 new NHS clinics will be opened over the five years, starting with the NHS Northern Gambling Service in Leeds and two satellite sites in Manchester and Sunderland.</p><p>GambleAware has indicated that it plans to provide over £1 million annually to the Leeds and York Partnership NHS Trust to fund the NHS Northern Gambling Clinic in Leeds, and £382,000 to the National Problem Gambling Clinic in London in 2019/20.</p><p> </p><p> </p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16964 question first answered 17/07/2019 13:35:43 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4308 label Biography information for The Lord Bishop of St Albans

1137100

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gambling: Rehabilitation
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how much funding GambleAware are projected to provide to the (1) NHS Northern Gambling Clinic in Leeds, and (2) the National Problem Gambling Clinic in London.
	tabling member printed	The Lord Bishop of St Albans
	uin	HL16964
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>As part of its NHS Long Term Plan, NHS England has made a commitment to invest in clinics to help more people with serious gambling problems. NHS England published its Long Term Plan Implementation Framework on 5 July 2019. The projected funding for gambling clinics was not separately identified and will be provided at a later date.</p><p>The first National Health Service gambling clinic for children will open this year as part of a new network of services for addicts being rolled out. Up to 15 new NHS clinics will be opened over the five years, starting with the NHS Northern Gambling Service in Leeds and two satellite sites in Manchester and Sunderland.</p><p>GambleAware has indicated that it plans to provide over £1 million annually to the Leeds and York Partnership NHS Trust to fund the NHS Northern Gambling Clinic in Leeds, and £382,000 to the National Problem Gambling Clinic in London in 2019/20.</p><p> </p><p> </p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16963 question first answered 17/07/2019 13:35:43 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4308 label Biography information for The Lord Bishop of St Albans

1137079

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Care Homes: Dental Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the report by the Care Quality Commission Smiling matters: oral health care in care homes, published on 24 June; and how they intend to respond.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL16943
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Government welcomes the report by the Care Quality Commission <em>Smiling matters: oral health care in care homes</em>. The Department together with Public Health England, NHS England and Health Education England is carefully considering the recommendations made in the report and will respond in due course.</p><p>This consideration includes the recommendations that NHS England work with partners in the health and care system to improve access both to high street and, where required domiciliary care for residents of care homes. As well as the recommendation that both local and national monitoring frameworks should include awareness and assessment of oral health including the National Institute of Health and Care Excellence guideline NG48.</p><p>NHS England is responsible for commissioning primary care dental services, including domiciliary care. Domiciliary care may be delivered by any dentist holding a contract to deliver general dental services or it may be specifically commissioned by NHS England locally as an additional service. Where such services have been specifically commissioned any concerns about delivery should be raised with NHS England. NHS England has a duty to provide services to meet local need, including domiciliary services.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16944 HL16945 HL16946 question first answered 17/07/2019 14:11:41 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1137080

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Care Homes: Dental Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they are taking to ensure that access to dental provision in care homes is improved.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL16944
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Government welcomes the report by the Care Quality Commission <em>Smiling matters: oral health care in care homes</em>. The Department together with Public Health England, NHS England and Health Education England is carefully considering the recommendations made in the report and will respond in due course.</p><p>This consideration includes the recommendations that NHS England work with partners in the health and care system to improve access both to high street and, where required domiciliary care for residents of care homes. As well as the recommendation that both local and national monitoring frameworks should include awareness and assessment of oral health including the National Institute of Health and Care Excellence guideline NG48.</p><p>NHS England is responsible for commissioning primary care dental services, including domiciliary care. Domiciliary care may be delivered by any dentist holding a contract to deliver general dental services or it may be specifically commissioned by NHS England locally as an additional service. Where such services have been specifically commissioned any concerns about delivery should be raised with NHS England. NHS England has a duty to provide services to meet local need, including domiciliary services.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16943 HL16945 HL16946 question first answered 17/07/2019 14:11:41 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1137081

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Care Homes: Dental Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what action they take to deal with dentists who are unwilling to visit care homes.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL16945
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Government welcomes the report by the Care Quality Commission <em>Smiling matters: oral health care in care homes</em>. The Department together with Public Health England, NHS England and Health Education England is carefully considering the recommendations made in the report and will respond in due course.</p><p>This consideration includes the recommendations that NHS England work with partners in the health and care system to improve access both to high street and, where required domiciliary care for residents of care homes. As well as the recommendation that both local and national monitoring frameworks should include awareness and assessment of oral health including the National Institute of Health and Care Excellence guideline NG48.</p><p>NHS England is responsible for commissioning primary care dental services, including domiciliary care. Domiciliary care may be delivered by any dentist holding a contract to deliver general dental services or it may be specifically commissioned by NHS England locally as an additional service. Where such services have been specifically commissioned any concerns about delivery should be raised with NHS England. NHS England has a duty to provide services to meet local need, including domiciliary services.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16943 HL16944 HL16946 question first answered 17/07/2019 14:11:41 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1137082

	registered interest
	date	04/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Care Homes: Dental Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they intend to take to ensure that care home services are made aware of NICE guideline NG48 Oral health for adults in care homes, published in July 2016.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL16946
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Government welcomes the report by the Care Quality Commission <em>Smiling matters: oral health care in care homes</em>. The Department together with Public Health England, NHS England and Health Education England is carefully considering the recommendations made in the report and will respond in due course.</p><p>This consideration includes the recommendations that NHS England work with partners in the health and care system to improve access both to high street and, where required domiciliary care for residents of care homes. As well as the recommendation that both local and national monitoring frameworks should include awareness and assessment of oral health including the National Institute of Health and Care Excellence guideline NG48.</p><p>NHS England is responsible for commissioning primary care dental services, including domiciliary care. Domiciliary care may be delivered by any dentist holding a contract to deliver general dental services or it may be specifically commissioned by NHS England locally as an additional service. Where such services have been specifically commissioned any concerns about delivery should be raised with NHS England. NHS England has a duty to provide services to meet local need, including domiciliary services.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16943 HL16944 HL16945 question first answered 17/07/2019 14:11:41 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1136423

	registered interest
	date	02/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have, if any, to extend the availability of medicinal cannabis to people with diseases that cause chronic pain.
	tabling member printed	Lord Jones of Cheltenham
	uin	HL16873
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16874 HL16875 question first answered 10/07/2019 15:30:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Impact_Assessment.pdf title Impact_Assessment
	tabling member	248 label Biography information for Lord Jones of Cheltenham